- Home
- BNR
as 04-23-2025 4:00pm EST
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
| Founded: | 2014 | Country: | China |
| Employees: | N/A | City: | N/A |
| Market Cap: | 30.9M | IPO Year: | 2020 |
| Target Price: | N/A | AVG Volume (30 days): | 20.3K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.62 - $8.99 | Next Earning Date: | 05-28-2025 |
| Revenue: | $70,669,261 | Revenue Growth: | -4.02% |
| Revenue Growth (this year): | 136.32% | Revenue Growth (next year): | -6.32% |
Latest Burning Rock Biotech Limited News
BNR Breaking Stock News: Dive into BNR Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
4 months ago
Burning Rock Announces Results of 2024 Annual General Meeting
TipRanks
5 months ago
Burning Rock Biotech’s Strategic Growth and Financial Results
GlobeNewswire
5 months ago
Burning Rock Reports Third Quarter 2024 Financial Results
GlobeNewswire
5 months ago
Burning Rock Announces 2024 Annual General Meeting to be Held on December 31, 2024
Simply Wall St.
6 months ago
Burning Rock Biotech Leads The Charge With 2 Other US Penny Stocks
MT Newswires
6 months ago
Update: Burning Rock Biotech, Dizal's Lung Cancer Diagnostic Gets China Marketing Approval; Shares Jump Premarket
MT Newswires
6 months ago
Burning Rock Biotech, Dizal's Non-Small Cell Lung Cancer Treatment , Diagnostic Receives China Marketing Approval
Compare BNR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BNR Burning Rock Biotech Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.